MARKET

APLS

APLS

Apellis Pharmace
NASDAQ
17.78
+0.36
+2.07%
After Hours: 17.78 0 0.00% 16:04 05/22 EDT
OPEN
17.14
PREV CLOSE
17.42
HIGH
17.87
LOW
17.07
VOLUME
1.69M
TURNOVER
--
52 WEEK HIGH
43.99
52 WEEK LOW
16.10
MARKET CAP
2.23B
P/E (TTM)
-9.9147
1D
5D
1M
3M
1Y
5Y
1D
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts
Benzinga · 4h ago
Apellis Pharmaceuticals Price Target Cut to $41.00/Share From $49.00 by Citigroup
Dow Jones · 4h ago
Apellis Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 4h ago
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $41
Benzinga · 5h ago
APELLIS PHARMACEUTICALS INC <APLS.O>: CITIGROUP CUTS TARGET PRICE TO $41 FROM $49
Reuters · 11h ago
Apellis price target lowered to $41 from $49 at Citi
TipRanks · 12h ago
The most crowded stocks by hedge funds based on their 13F filings
Seeking Alpha · 1d ago
Apellis Pharmaceuticals: Have Some Patience
Seeking Alpha · 2d ago
More
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Webull offers Apellis Pharmaceuticals Inc stock information, including NASDAQ: APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.